Full trial results of EASE-SBS 1 expected in the third quarter of 2022 Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback